Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2026-04-10 20:53:18 ET · period of report 2026-04-10 · accession 0001193125-26-151628 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-10 20:53 | 2026-04-10 | ANTX | Marks Gilbert Lynn | Dir | A - Grant | $0.00 | +3,775 | 79.1K | +5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-10 | A | A | 3,775 | $0.00 | 79,084 | D | — | — | (F1) Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately. |